Table 1.
Baseline characteristics of the COVID-19-infected study cohort on hospital admission (n = 490 study participants)
| Characteristic | Non-missing cases | Statistics |
|---|---|---|
| Demographics | ||
| Age (years)a | 481 | 67 ± 18 72 [55, 81] |
| Gender (female: male)a | 482 | 42 (203): 58 (279) |
| BMI (kg/m2) | 81 | 28 ± 8 25 [23, 31] |
| Symptoms | ||
| Cougha | 453 | 58 (264) |
| Fever (> 38,5 °C)a | 448 | 46 (205) |
| Dyspneaa | 448 | 57 (256) |
| Vital parameters | ||
| Heart rate (/min)a | 451 | 88 ± 19 86 [76, 100] |
| Systolic blood pressure (mmHg)a | 446 | 133 ± 22 130 [120, 145] |
| Respiratory rate (/min)a | 356 | 20 ± 6 18 [15, 22] |
| spO2 (%)a | 442 | 93,3 ± 5,8 95 [91, 97] |
| Laboratory findings | ||
| Lymphocytes (/nl) | 294 | 1.73 ± 3.48 1.00 [0.66, 1.40] |
| Leukocytes (/nl)a | 478 | 7.9 ± 4.1 6.9 [5.1, 9.6] |
| Neutrophile granulocytes (/nl) | 315 | 6,5 ± 10,9 4,8 [3.3, 7.3] |
| Creatinine (mg/dl)a | 474 | 1,37 ± 1,59 1.0 [0.80, 1.40] |
| C-reactive protein (mg/l)a | 474 | 84 ± 80 64 [23, 118] |
| Lactate dehydrogenase (U/l)a | 358 | 417 ± 745 322 [252, 448] |
| aPTT (s)a | 370 | 35 ± 16 32 [29, 36] |
| Potassium (mmol/l)a | 455 | 4.04 ± 0.60 3.99 [3.66, 4.36] |
| Procalcitonin (µg/l) | 321 | 1.32 ± 10.37 0.09 [0.05, 0.25] |
| pH | 369 | 7.43 [7.40, 7.46] |
| pO2 (mmHg) | 361 | 55 ± 40 50 [28, 68] |
| pCO2 (mmHg) | 367 | 39 ± 9 37 [33, 43] |
| sO2 (mmHg) | 363 | 54 ± 35 56 [25, 89] |
| Comorbidities | ||
| Total number of comorbiditiesa | 445 | – |
| No comorbidity | 27 (122) | |
| 1 comorbidity | 22 (100) | |
| 2 comorbidities | 21 (95) | |
| 3 comorbidities | 15 (67) | |
| 4 comorbidities | 8.8 (39) | |
| 5 comorbidities | 3.4 (15) | |
| 6 comorbidities | 1.6 (7) | |
| Type of comorbidities | ||
| Chronic kidney disease | 468 | 18 (86) |
| Pulmonary disease | 462 | 18 (82) |
| Diabetes mellitus | 471 | 24 (112) |
| Dyslipidemia | 451 | 14 (65) |
| Vascular/coronary artery disease | 490 | 27 (131) |
| Hypertension | 461 | 57 (265) |
| Cardiomyopathy | 461 | 5.2 (24) |
| Tumor diseasea | 190 | 19 (93) |
| Medication | ||
| Antiplatelet medicationa | 490 | 27(130) |
| RAAS-Inhibitorsa | 490 | 42 (204) |
| Antidiabetic medicationa | 490 | 22 (106) |
| Immunosuppressive medicationa | 490 | 18 (87) |
| Statinsa | 459 | 21 (96) |
| Oral anticoagulationa | 467 | 14 (67) |
| Diureticsa | 457 | 24 (110) |
| Proton pump inhibitorsa | 453 | 30 (135) |
Continuous data are displayed as mean ± standard deviation/median [first quartile, third quartile], Categorical data are displayed as proportion (total number)
BMI, body mass index, spO2, saturation of peripheral oxygen, aPTT, activated partial thromboplastin time, pO2, partial pressure of oxygen, pCO2, partial pressure of carbon dioxide, sO2, saturation of oxygen, RAAS-Inhibitors, renin–angiotensin–aldosterone system-Inhibitors
aVariables included into the analysis